Locomotor Effects of Lisuride: a Consequence of Dopaminergic and Serotonergic Actions

Overview

Journal Psychopharmacology (Berl)

Specialty Pharmacology

Date 1985 Jan 1

PMID 2991961

Citations 2

Authors

H Fink

R Morgenstern

Affiliations

Soon will be listed here.

Abstract

The open-field test was used to study the involvement of serotonergic and dopaminergic mechanisms in the action of lisuride on locomotor activity in the rat. Lisuride produced a biphasic locomotor effect. The maximum locomotor stimulatory response of lisuride was stronger than that of apomorphine and comparable with that of apomorphine and LSD combined. Hypermotility induced by high doses of lisuride was partially suppressed by the serotonin antagonist cyproheptadine and not further enhanced by LSD. A moderate dose of lisuride potentiated apomorphine-induced hypermotility in the same manner as has been shown for LSD. Lesion of dopaminergic structures within the median raphe nucleus by 6-OHDA produced a potentiation of lisuride-induced hypermotility. This effect was suppressed by cyproheptadine. The locomotor inhibitory effect of low doses of lisuride may be related to a stimulation of presynaptic mesolimbic dopamine receptors. It is concluded that the locomotor stimulant effect of higher doses of lisuride may depend on stimulation of postsynaptic dopamine receptors and a serotonergic action and that the locomotor effects of lisuride reflect a complex interaction at dopaminergic and serotonergic transmission systems.

Citing Articles

Comparative Pharmacological Effects of Lisuride and Lysergic Acid Diethylamide Revisited.

Glatfelter G, Pottie E, Partilla J, Stove C, Baumann M ACS Pharmacol Transl Sci. 2024; 7(3):641-653.

PMID: 38481684 PMC: 10928901. DOI: 10.1021/acsptsci.3c00192.

The G protein biased serotonin 5-HT2A receptor agonist lisuride exerts anti-depressant drug-like activities in mice.

Pogorelov V, Rodriguiz R, Roth B, Wetsel W Front Mol Biosci. 2023; 10:1233743.

PMID: 37900918 PMC: 10603247. DOI: 10.3389/fmolb.2023.1233743.

References

Marini J, Jacobs B, Sheard M, Trulson M . Activity of a non-hallucinogenic ergoline derivative, lisuride, in an animal behavior model for hallucinogens. Psychopharmacology (Berl). 1981; 73(4):328-31. DOI: 10.1007/BF00426460. View

Pieri L, Keller H, BURKARD W, Da Prada M . Effects of lisuride and LSD on cerebral monoamine systems and hallucinosis. Nature. 1978; 272(5650):278-80. DOI: 10.1038/272278a0. View

Gold R, Morgenstern R, Fink H . Effects of atypical antidepressants on LSD potentiated apomorphine hypermotility in rats. Acta Biol Med Ger. 1980; 39(8-9):917-21. View

Holzel B, Pfister C, Fink H . [Morphological changes in the neurons of the rat nucleus raphe dorsalis following application of 5,7-dihydroxytryptamine. A golgi-rapid-impregnation study]. J Hirnforsch. 1984; 25(3):343-9. View

Silbergeld E, Hruska R . Lisuride and LSD: dopaminergic and serotonergic interactions in the "serotonin syndrome". Psychopharmacology (Berl). 1979; 65(3):233-7. DOI: 10.1007/BF00492209. View

Carruba M, Ricciardi S, Muller E, Mantegazza P . Anorectic effect of lisuride and other ergot derivatives in the rat. Eur J Pharmacol. 1980; 64(2-3):133-41. DOI: 10.1016/0014-2999(80)90036-9. View

Rogawski M, Aghajanian G . Response of central monoaminergic neurons to lisuride: comparison with LSD. Life Sci. 1979; 24(14):1289-97. DOI: 10.1016/0024-3205(79)90148-6. View

White F, Wang R . Comparison of the effects of LSD and lisuride on A10 dopamine neurons in the rat. Neuropharmacology. 1983; 22(6):669-76. DOI: 10.1016/0028-3908(83)90089-8. View

Fink H, Morgenstern R, OELSSNER W . Psychotomimetics potentiate locomotor hyperactivity induced by dopaminergic drugs. Pharmacol Biochem Behav. 1979; 11(5):479-82. DOI: 10.1016/0091-3057(79)90028-5. View

10.

Rosenfeld M, MAKMAN M . The interaction of lisuride, an ergot derivative, with serotonergic and dopaminergic receptors in rabbit brain. J Pharmacol Exp Ther. 1981; 216(3):526-31. View

11.

Morgenstern R, Fink H, OELSSNER W . LSD-potentiated apomorphine hypermotility: a model for differentiating antipsychotic drugs. Pharmacol Biochem Behav. 1983; 18(1):13-7. DOI: 10.1016/0091-3057(83)90243-5. View

12.

Cote T, Munemura M, Kebabian J . Lisuride hydrogen maleate: an ergoline with beta-adrenergic antagonist activity. Eur J Pharmacol. 1979; 59(3-4):303-6. DOI: 10.1016/0014-2999(79)90295-4. View

13.

Fink H, OELSSNER W . LSD mescaline and serotonin injected into medial raphe nucleus potentiate apomorphine hypermotility. Eur J Pharmacol. 1981; 75(4):289-96. DOI: 10.1016/0014-2999(81)90556-2. View

14.

Weir R, Hruska R, Silbergeld E . Binding of antiparkinsonian ergot derivatives to the dopamine receptor. Psychopharmacology (Berl). 1981; 75(2):119-23. DOI: 10.1007/BF00432172. View

15.

Fink H, Morgenstern R, OELSSNER W . Clozapine--a serotonin antagonist?. Pharmacol Biochem Behav. 1984; 20(4):513-7. DOI: 10.1016/0091-3057(84)90297-1. View

16.

KEHR W . Effect of lisuride and other ergot derivatives on monoaminergic mechanisms in rat brain. Eur J Pharmacol. 1977; 41(3):261-73. DOI: 10.1016/0014-2999(77)90319-3. View

17.

Tissari A, Rossetti Z, Meloni M, Frau M, Gessa G . Autoreceptors mediate the inhibition of dopamine synthesis by bromocriptine and lisuride in rats. Eur J Pharmacol. 1983; 91(4):463-8. DOI: 10.1016/0014-2999(83)90171-1. View

18.

Fink H, Morgenstern R . The role of the median raphe nucleus in sulpiride-induced potentiation of apomorphine hypermotility. Eur J Pharmacol. 1984; 99(1):123-4. DOI: 10.1016/0014-2999(84)90443-6. View

19.

Horowski R, Wachtel H . Direct dopaminergic action of lisuride hydrogen maleate, an ergot derivative, in mice. Eur J Pharmacol. 1976; 36(2):373-83. DOI: 10.1016/0014-2999(76)90091-1. View